Skip to main content
NBP logo

NBP

NovaBridge Biosciences
$1.90 +0.04 (+2.15%) At close · Jul 10
Market Cap
$493.60M
Shares
265,377,891

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.90 Open$1.87 Day$1.75–1.91 52W$1.46–6.79 Avg vol 30d684K Short int3.5M · 1.3% float · 4.1d Short vol64% DataJan 2020–Jul 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026 Est
Equibles Rating blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15 · calm Equity put/call 0.55
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −42%
below
Price vs 50-day avg +2%
above
RSI (14) 54
neutral
MACD trend Positive
52-week position 8%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +24%
trailing
6-month return −48%
trailing
YTD return −52%
this year
Relative strength −57%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Distributing
-16% holders QoQ · +8 funds added
Insider flow Accumulating
Net +$511.4K over 90 days · 75% sells
Short interest Falling
1.31% of float · ▼ -16.6% MoM · 4.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
49 holders — mid 3-yr range
Squeeze score 56
elevated · 0–100
Fundamentals
Strong
Revenue growth +141%
Y/Y
EPS growth −75%
Y/Y
Free cash flow $-183.8M
Buyback $40.0M
authorized
Balance sheet $210.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 96%
annualized · 1-yr
Max drawdown −78%
past year
ATR 8.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−42% Bearish
Price vs 50-day avg
+2% Bullish
RSI (14)
54 Neutral
MACD trend
Positive Bullish
52-week position
8% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Distributing
-16% holders QoQ · +8 funds added
Insider flow Accumulating
Net +$511.4K over 90 days · 75% sells
Short interest Falling
1.31% of float · ▼ -16.6% MoM · 4.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
49 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1 Now $2 · 8% 52-wk high $7
vs 200-day avg -42% vs 50-day avg +2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NBP
NovaBridge Biosciences
this stock
$493.60M -52.3% +140.7% 1.3%
ONC
BeOne Medicines Ltd.
$431.70B -1.7% +22179.2% 878.5 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$123.19B +9.5% +46.2% 28.8 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$69.63B -13.8% +20.8% 16.2 3.3%
ARGX
Argenx SE
$54.85B +8.2% 2.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
49
% held
11.1%
Net QoQ
-3.9M sh
Top holder
JANUS HENDERSON GROUP PLC
Held Float
View
Held by Funds
Fund positions
15
View
Short & Settlement
Short Interest Falling
Shares short
3.5M
Days to cover
4.1d
Change
-692.1K sh
View
Short Volume
Short vol %
64%
As of
Jul 10, 2026
Short Total
View
Fails to Deliver
FTD shares
2.0K
Value
$3.0K
As of
Jun 11, 2026
View
Off-Exchange
Off-exchange %
39.2%
Week of
May 4, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$511.4K
Buyers / Sellers
1 / 3
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$632.0K
Net income (FY)
$-46.3M
EPS diluted
$-0.21
View
Buybacks
Authorized
$40.0M
View
Filings
SEC Filings
Latest
6-K
Filed
Jun 29, 2026
This year
17
View
Proposed Sales
Value
$18.5K
Shares
9.3K
Filed
May 14, 2026
View

Performance

5D 20D 120D MTD YTD
NBP -11.2% +24.2% -48.1% -2.6% -52.3%
SPY +0.8% +2.0% +8.9% +0.7% +10.2%
vs SPY -12.0% +22.2% -57.0% -3.2% -62.5%

Capital returns

Buyback program · as of Dec 31, 2025
Authorized
$40.00M
Spent (derived)
Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1778016 CUSIP 44975P103 13F (30d) 7 filings 1 filers Visit website